Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

12.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.1K
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

8.7K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
8.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: STAT3 promotes NLRP3 inflammasome activation by mediating NLRP3 mitochondrial translocation.

Experimental & molecular medicine·2024
Same author

STAT3 promotes NLRP3 inflammasome activation by mediating NLRP3 mitochondrial translocation.

Experimental & molecular medicine·2024
Same author

Acetylation is required for full activation of the NLRP3 inflammasome.

Nature communications·2023
Same author

Z-DNA binding protein 1 promotes heatstroke-induced cell death.

Science (New York, N.Y.)·2022
Same author

YAP promotes the activation of NLRP3 inflammasome via blocking K27-linked polyubiquitination of NLRP3.

Nature communications·2021
Same author

Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients.

Cancer immunity·2013

Related Experiment Video

Updated: Jan 17, 2026

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
09:04

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

21.4K

GSK461364 Inhibits NLRP3 Inflammasome by Targeting NEK7 Phosphorylation.

Ruiheng Luo1, Mingliang Ma1, Dan Wang2

  • 1Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410000, P. R. China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|September 15, 2025
PubMed
Summary

GSK461364 effectively inhibits the NLRP3 inflammasome by targeting PLK1, offering a promising new therapeutic strategy for inflammatory diseases. This compound demonstrates protective effects in preclinical models, highlighting its potential in treating conditions linked to aberrant inflammasome activation.

Keywords:
GSK461364NEK7NLRP3 inflammasomePLK1

More Related Videos

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

11.2K
Evaluation of Caspase Activation to Assess Innate Immune Cell Death
10:23

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

3.8K

Related Experiment Videos

Last Updated: Jan 17, 2026

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
09:04

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

21.4K
Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

11.2K
Evaluation of Caspase Activation to Assess Innate Immune Cell Death
10:23

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

3.8K

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • The NLRP3 inflammasome is a key mediator of inflammation, and its dysregulation is linked to numerous inflammatory disorders.
  • Existing small-molecule inhibitors targeting the NLRP3 inflammasome have shown limited success in clinical applications.
  • Understanding the precise regulatory mechanisms of NLRP3 inflammasome activation is crucial for developing effective therapeutics.

Purpose of the Study:

  • To identify novel inhibitors of the NLRP3 inflammasome.
  • To investigate the therapeutic potential of GSK461364 in preclinical models of inflammation.
  • To elucidate the molecular mechanism by which GSK461364 inhibits NLRP3 inflammasome activation.

Main Methods:

  • Screening of a kinase compound library to identify NLRP3 inflammasome inhibitors.
  • Evaluation of GSK461364 efficacy in murine models of LPS-induced endotoxemia and DSS-induced colitis.
  • Mechanistic studies to determine the molecular target and pathway of GSK461364 action.

Main Results:

  • GSK461364 was identified as a potent and selective inhibitor of the NLRP3 inflammasome.
  • GSK461364 demonstrated significant protective effects in mouse models of endotoxemia and colitis.
  • GSK461364 was found to target Polo-like Kinase 1 (PLK1), inhibiting PLK1-mediated phosphorylation of NEK7, which is critical for NLRP3 inflammasome assembly.

Conclusions:

  • GSK461364 represents a novel therapeutic candidate for treating NLRP3 inflammasome-driven inflammatory diseases.
  • The study reveals PLK1 as a key regulator of NLRP3 inflammasome activation via NEK7 phosphorylation.
  • These findings offer new insights into post-translational modification in inflammasome regulation and therapeutic targeting.